title: Fat and carbohydrate metabolism during exercise in late-onset Pompe disease.
abstract: Pompe disease is caused by absence of the lysosomal enzyme acid alpha-glucosidase. It is generally assumed that intra-lysosomal hydrolysis of glycogen does not contribute to skeletal muscle energy production during exercise. However, this hypothesis has never been tested in vivo during exercise. We examined the metabolic response to exercise in patients with late-onset Pompe disease, in order to determine if a defect in energy metabolism may play a role in the pathogenesis of Pompe disease. We studied six adult patients with Pompe disease and 10 healthy subjects. The participants underwent ischemic forearm exercise testing, and peak work capacity was determined. Fat and carbohydrate metabolism during cycle exercise was examined with a combination of indirect calorimetry and stable isotope methodology. Finally, the effects of an IV glucose infusion on heart rate, ratings of perceived exertion, and work capacity during exercise were determined. We found that peak oxidative capacity was reduced in the patients to 17.6 vs. 38.8 ml kg(-1) min(-1) in healthy subjects (p = 0.002). There were no differences in the rate of appearance and rate of oxidation of palmitate, or total fat and carbohydrate oxidation, between the patients and the healthy subjects. None of the subjects improved exercise tolerance by IV glucose infusion. In conclusion, peak oxidative capacity is reduced in Pompe disease. However, skeletal muscle fat and carbohydrate use during exercise was normal. The results indicate that a reduced exercise capacity is caused by muscle weakness and wasting, rather than by an impaired skeletal muscle glycogenolytic capacity. Thus, it appears that acid alpha-glucosidase does not play a significant role in the production of energy in skeletal muscle during exercise.
authors.affiliation: Neuromuscular Research Unit, Department of Neurology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. npreisler@hotmail.com
authors.forename: Nicolai
authors.initials: N
authors.lastname: Preisler
authors.forename: Pascal
authors.initials: P
authors.lastname: Laforet
authors.forename: Karen Lindhardt
authors.initials: KL
authors.lastname: Madsen
authors.forename: Regitze Sølling
authors.initials: RS
authors.lastname: Hansen
authors.forename: Zoltan
authors.initials: Z
authors.lastname: Lukacs
authors.forename: Mette Cathrine
authors.initials: MC
authors.lastname: Ørngreen
authors.forename: Arnaud
authors.initials: A
authors.lastname: Lacour
authors.forename: John
authors.initials: J
authors.lastname: Vissing
mesh_terms: D017668:Age of Onset; D002153:Calorimetry, Indirect; D016022:Case-Control Studies; D015444:Exercise; D005227:Fatty Acids / Q000378:metabolism*; D005260:Female; D005947:Glucose / Q000008:administration & dosage; D006003:Glycogen / Q000378:metabolism*; D006009:Glycogen Storage Disease Type II / Q000378:metabolism* / Q000473:pathology; D050261:Glycogenolysis; D006801:Humans; D007262:Infusions, Intravenous; D007553:Isotope Labeling; D008297:Male; D018908:Muscle Weakness / Q000378:metabolism* / Q000473:pathology; D018482:Muscle, Skeletal / Q000378:metabolism* / Q000473:pathology; D010101:Oxygen Consumption; D005082:Physical Exertion; D000520:alpha-Glucosidases / Q000378:metabolism
chemical_list: D005227:Fatty Acids; D006003:Glycogen; D000520:alpha-Glucosidases; D005947:Glucose